Vemurafenib Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 240 mg
Reference Brands: Zelboraf (USA/EU), Vemura (India)
Category:
Oncology Cancer Care
Vemurafenib is available in Tablets
and strengths such as 240 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Vemurafenib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Vemurafenib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Vemurafenib is a targeted anticancer medication used primarily for the treatment of metastatic or unresectable melanoma that carries a BRAF V600 mutation. It is a selective BRAF inhibitor that works by blocking the activity of the mutated BRAF V600E kinase, a protein involved in the MAPK signaling pathway that promotes tumor cell growth and proliferation. By inhibiting this pathway, vemurafenib helps slow down or stop the growth of cancer cells and supports better disease control in affected patients.
The drug has been approved for use in patients with BRAF-mutant melanoma and is also indicated for certain rare conditions such as Erdheim-Chester disease. In clinical practice, vemurafenib may sometimes be used in other cancers that carry BRAF mutations, including refractory non-small cell lung cancer and papillary thyroid cancer, when appropriate treatment options are limited. Clinical trials such as the BRIM studies demonstrated significant improvements in survival outcomes for patients with BRAF-mutant melanoma, which contributed to its regulatory approval.
While effective, treatment with vemurafenib may cause side effects such as skin reactions, rash, and increased sensitivity to sunlight. Because of potential risks, patients receiving this therapy require regular monitoring of liver, kidney, and heart function to ensure safe and effective treatment.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing